Syndax Pharmaceuticals (NASDAQ: SNDX)
Syndax Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Syndax Pharmaceuticals Company Info
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
News & Analysis
Why Syndax Pharmaceuticals Stock Is Sinking Today
The company announced results from an early-stage clinical study.
Why Syndax Is Skyrocketing 55% Today
Initial data from an early-stage leukemia trial is promising.
3 Biotech Stocks That Soared This Week: Are They Buys?
Can these sizzling biotech stocks keep the momentum going?
Here's Why Syndax Pharmaceuticals Is Soaring Today
Traders cheer the release of a bullish note from a major investment firm.
3 Under-the-Radar Stocks in the Healthcare Sector
Syndax Pharmaceuticals, Corcept Therapeutics, and LeMaitre Vascular might not be household names, but they are companies investors should get to know.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.